Our previous studiesshowed that romiplostim synergized with rHuEPOto promote RBCs production while rHuEPO restores the platelet countto the normal physiological range through megakaryocyte–erythroidprogenitors (MEPs) competition, thus reducing the risk of thrombosiscaused by the romiplostim-induced increase in the platelet count.17 Therefore, the combination of EPO and romiplostimcan potentially be used to treat anemia in patients who are resistantto EPO alone. Here, EPO is linked to anemia (phenotype).